Prevalence of extended-spectrum β-lactamases in Enterobacter cloacae in Taiwan and comparison of 3 phenotypic confirmatory methods for detecting extended-spectrum β-lactamase production

Journal of Microbiology, Immunology and Infection

Volumn 42, Issue 4, 2009, Pages 310-316

  Yang, Jia Ling ^a   Wang, Jann Tay ^a   Lauderdale, Tsai Ling ^b   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Beta lactamases; Enterobacter cloacae; Prevalence; Taiwan

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROBACTER CLOACAE; ENZYME SYNTHESIS; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; SENSITIVITY AND SPECIFICITY; TAIWAN;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PREVALENCE; TAIWAN;

EID: 74849126279     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y. Regional variation in the prevalene of extended-spectrum beta-lactamase- producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis. 2005;52:323-9.
2. Luzzaro F, Perilli M, Migliavacca R. Repeated epidemics caused by extended-spectrum beta-lactamase-producing Serratia marcescens strains. Eur J Clin Microbiol Infect Dis. 1998;17:629-36.
3. De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J. A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group. Antimicrob Agents Chemother. 2000;44:3177-9.
4. Bell JM, Turnidge JD, Jones RN. Prevalence of extended-spectrum beta-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001. Antimicrob Agents Chemother. 2003;47:3989-93.
5. Yu WL, Cheng KC, Chi CJ, Chen HE, Chuang YC, Wu LT. Characterization and molecular epidemiology of extended-spectrum beta-lactamase-producing Enterobacter cloacae isolated from a district teaching hospital in Taiwan. Clin Microbiol Infect. 2006;12:579-82.
6. Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis. 2001;7:333-6.
7. Tzelepi E, Giakkoupi P, Sofianou D, Loukova V, Kemeroglou A, Tsakris A. Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol. 2000;38:542-6.
8. Sturenburg E, Sobottka I, Noor D, Laufs R, Mack D. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother. 2004;54:134-8.
9. Lauderdale TL, Clifford McDonald L, Shiau YR, Chen PC, Wang HY, Lai JF, et al; TSAR Participating Hospitals. The status of antimicrobial resistance in Taiwan among Gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis. 2004;48:211-9.
10. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. CLSI document, M100-S17. Wayne: Clinical and Laboratory Standards Institute; 2007.
11. Lee SH, Kim JY, Lee SK, Jin W, Kang SG, Lee KJ. Discriminatory detection of extended-spectrum β-lactamases by restriction fragment length dimorphism-polymerase chain reaction. Lett Appl Microbiol. 2000;31:307-12.
12. Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β-lactamases. J Antimicrob Chemother. 2006;57:154-5.
13. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother. 2001;48(Suppl 1):S87-102.
14. Choi SH, Lee JE, Park SJ, Kim MN, Choo EJ, Kwak YG. Prevalence, microbiology, and clinical characteristics of extended-spectrum beta-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea. Eur J Clin Microbiol Infect Dis. 2007;26:557-61.
15. Wu TL, Chia JH, Su LH, Chu C, Kuo AJ, Chiu CH. Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units of a medical center in Taiwan. Microb Drug Resist. 2006;12:203-9.
16. Liu CP, Wang NY, Lee CM, Weng LC, Tseng HK, Liu CW, et al. Nosocomial and community-acquired Enterobacter cloacae bloodstream infection: risk factors for and prevalence of SHV-12 in multiresistant isolates in a medical centre. J Hosp Infect. 2004;58:63-77.
17. Varela C, Oliver A, Coque TM, Baquero F, Canton R. Prevalence of extended-spectrum beta-lactamases in group-1 beta-lactamase-producing isolates. Clin Microbiol Infect. 2001;7:278-82.
18. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. Diagn Microbiol Infect Dis. 1994;19:33-8.
19. Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003;47:3442-7.
20. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460-3.
21. Martinez-Martinez L. Extended-spectrum beta-lactamases and the permeability barrier. Clin Microbiol Infect. 2008;14(Suppl 1):82-9.
22. Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents. 2009;33:130-6.